Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities

    131 Citationer (Scopus)

    Abstract

    Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone, secreted in response to ingestion of nutrients, and has important effects on several of the pathophysiological features of type 2 diabetes (T2D). The effects include potentiation of insulin secretion, suppression of glucagon secretion, slowing of gastric emptying and suppression of appetite. In circulation, GLP-1 has a half-life of approximately 2min due to rapid degradation by the enzyme dipeptidyl peptidase 4 (DPP-4). Because of this short half-life GLP-1 receptor (GLP-1R) agonists, resistant to degradation by DPP-4 have been developed. At the moment four different compounds are available for the treatment of T2D and many more are in clinical development. These compounds, although all based on the effects of native GLP-1, differ with regards to structure, pharmacokinetics and size, which ultimately leads to different clinical effects. This review gives an overview of the clinical data on GLP-1R agonists that have been compared in head-to-head studies and focuses on relevant differences between the compounds. Highlighting these similarities and differences could be beneficial for physicians in choosing the best treatment strategy for their patients.

    OriginalsprogEngelsk
    TidsskriftEuropean Journal of Internal Medicine
    Vol/bind25
    Udgave nummer5
    Sider (fra-til)407-14
    Antal sider8
    ISSN0953-6205
    DOI
    StatusUdgivet - jun. 2014

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities'. Sammen danner de et unikt fingeraftryk.

    Citationsformater